Bet­ter than CAR-T? Al­ready prep­ping for a US launch, Mor­phoSys posts stel­lar DL­B­CL da­ta to field against No­var­tis, Gilead

Al­ready beaver­ing away at build­ing a US com­mer­cial op­er­a­tion, Mor­phoSys $MOR is now bear­ing down on No­var­tis and Gilead with a po­ten­tial CAR-T killer soon to be put in­to the hands of US reg­u­la­tors.

The Ger­man biotech says its fi­nal cut of the da­ta on their CD19-tar­get­ing an­ti­body taf­a­sita­m­ab — or MOR208 — com­bined with lenalido­mide crossed the fin­ish line in a group of pa­tients suf­fer­ing from treat­ment-re­sis­tant DL­B­CL, a com­mon form of non-Hodgkin lym­phoma.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER